Frankfurt
13.08.25 | 08:02
0,073 Euro
+3,24 % +0,002
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,102 | 0,104 | 17:11 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | Mauna Kea Technologies Reports First Half 2025 Revenue | 315 | Business Wire | On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2 Record U.S. sales productivity despite ongoing safeguard procedure Total revenue down 5% amid weaker EMEA and... ► Artikel lesen | |
| 24.07. | Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership | 242 | Business Wire | Leveraging strong momentum for the CellTolerance® application, Mauna Kea Technologies is expanding into new geographies with high growth potential Regulatory clearance in Australia (TGA) expected... ► Artikel lesen | |
| 21.07. | Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S. | 249 | Business Wire | 14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property An ecosystem built around the Cellvizio® platform, enabling partners to develop advanced... ► Artikel lesen | |
| 15.07. | Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio | 393 | Business Wire | Clinical team at Stanford Health Care achieved the CellTolerance 100-case milestone with the Cellvizio® platform in less than 6 months The CellTolerance® test offers IBS patients a way to detect... ► Artikel lesen | |
| 10.07. | Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure | 543 | Business Wire | Bridge financing through the issuance of convertible bonds to Vester Finance and European investors for €1.8m Immediate receipt of the entire financing upon signing Cash runway extended to... ► Artikel lesen | |
| 10.07. | Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure | 385 | Business Wire | Structuring of financing in progress to secure the safeguard period and support long-term development plan Authorization to implement the classes of affected parties proceeding, paving the way... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 07.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 236 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025 | 476 | Business Wire | All the resolutions proposed by the Board of Directors were adopted
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 331 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 02.06. | Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification | 475 | Business Wire | Cellvizio technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient management Results build on new CLIMB study data recently... ► Artikel lesen | |
| 21.05. | Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress | 413 | Business Wire | Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers of Excellence Adopting the Technology, Including a... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 5, 2025 and the Instructions for Participation | 1.042 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 06.05. | Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week 2025 | 868 | Business Wire | Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the diagnosis and treatment of pancreatic cystic lesions... ► Artikel lesen | |
| 05.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 681 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2024 Annual Financial Report | 779 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio in Key Indications | 432 | Business Wire | Pancreatic cyst abstracts build on endorsement of Cellvizio by Europe's leading endoscopy society, ESGE, as a key tool for improving pancreatic cyst diagnostic accuracy AI, pancreatic cancer... ► Artikel lesen | |
| 24.04. | Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update | 928 | Business Wire | Commercial activities remain strong, including CellTolerance launch Recently approved safeguard proceeding yielding productive creditor and investor discussions aimed at strengthening Mauna Kea's... ► Artikel lesen | |
| 07.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 308 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF Listing: Euronext Growth Paris
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing:... ► Artikel lesen | |
| 01.04. | Mauna Kea Technologies Announces Entrance Into Exclusive Negotiations for a Licensing Agreement for Cellvizio in an Important Therapeutic Area With a Major Industry Player | 507 | Business Wire | The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify... ► Artikel lesen | |
| 31.03. | Mauna Kea Technologies Announces the Opening of a Safeguard Proceeding to Restructure Its Financial Liabilities | 709 | Business Wire | The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The procedure will also provide a protective framework favorable... ► Artikel lesen |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,115 | -3,36 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| FAMICORD | 5,200 | 0,00 % | Original-Research: FamiCord AG (von Montega AG): Kaufen | Original-Research: FamiCord AG - von Montega AG 06.06.2025 / 17:08 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,130 | 0,00 % | Dividendenbekanntmachungen (28.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ASML HOLDING NV NL0010273215 - 1,6 EUR ATHOS IMMOBILIEN AG AT0000616701 - 0,8 EUR BRINKS COMPANY US1096961040 0,255 USD 0,2171 EUR DISO... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,631 | -13,35 % | Plus Therapeutics files to sell 33M shares of common stock for holders | ||
| ATOSSA THERAPEUTICS | 0,680 | +2,72 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update | FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required
Strong... ► Artikel lesen | |
| MEDICLIN | 2,960 | -1,99 % | EQS-News: MEDICLIN AG: MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025
31.07.2025 / 13:13 CET/CEST
Für... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results | Revenues increased 18% compared to same period last yearU.S. revenue increased 57% compared to same period last yearNet loss per share decreased 43% compared to same period last year BOULDER, COLORADO... ► Artikel lesen | |
| VERU | 0,298 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA8959792018 Trilogy AI Corp. 08.08.2025 CA88909Q1090 Tokenwell Platforms Inc. 11.08.2025 Tausch 1:1US92536C1036 Veru... ► Artikel lesen | |
| LIFEWARD | 0,710 | +1,73 % | Lifeward Ltd.: Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| LIGHT AI | 0,179 | +2,87 % | Light AI Inc: Light AI talks up development of wellness application | ||
| MAVEN BRANDS | 0,001 | 0,00 % | Maven Brands Inc: Maven Brands to sell subdivided Lumby land for $3.5M | ||
| EKSO BIONICS | 3,090 | +6,19 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| FRESENIUS | 45,390 | +2,79 % | Fresenius erhöht Wachstumsprognose - Quartal beim Ergebnis stärker als gedacht | BAD HOMBURG (dpa-AFX) - Der Krankenhausbetreiber und Arzneimittelkonzern Fresenius hat nach dem zweiten Quartal seine Prognose für das Wachstum angehoben. Die Gewinnprognose wurde dagegen bestätigt.... ► Artikel lesen | |
| ECKERT & ZIEGLER | 19,510 | - | Medizintechniker aus dem SDAX: Eckert & Ziegler-Aktie mit Vollbremsung: Große Hoffnungen für die Krebstherapie | © Foto: Lexmouth - Eckert & ZieglerInnerhalb eines Jahres hat sich die Aktie des Spezialisten für Nuklearmedizin fast verdoppelt. Nach den jüngsten Zahlen folgt der Rücksetzer. Der Berliner Strahlen-... ► Artikel lesen |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,24 % bei einem Aktienkurs von 0,073 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.